What emerging trends in the FDA’s most coveted designations might tell us
Marked shifts in the pursuit and grant of high-order designations raise fascinating questions. What factors might be driving the sharp downturns in CDER breakthrough designations? And does the sharp post-pandemic upturn in high-order designations by CBER represent a shifting of enthusiasm in favor of advanced therapies? This report, analyzing recent data from the FDA, gives critical insights into market shifts in high-order designations and what it might mean for drug developers.
Related Insights
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Preparing for the New Era of Hybrid Regulatory Inspections
Jul 11, 2022
Blog
Three Ways Early-Stage Companies Can Attract Investors
Feb 3, 2022
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Article
Getting to ‘No’ fast is more important when you are small
Mar 4, 2022
Related Insights
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Preparing for the New Era of Hybrid Regulatory Inspections
Jul 11, 2022
Blog
Three Ways Early-Stage Companies Can Attract Investors
Feb 3, 2022
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Article
Getting to ‘No’ fast is more important when you are small
Mar 4, 2022